OTC · Biotechnology

Anthera Pharmaceuticals, Inc. (ANTH) Stock

$0.00 OTC: ANTH Healthcare

Anthera Pharmaceuticals, Inc., a biopharmaceutical enterprise, concentrates on developing and commercializing therapeutic solutions for conditions with significant unmet medical needs. The company's pipeline includes Sollpura, an investigational non-porcine pancreatic enzyme replacement therapy in Phase III clinical trials for individuals with exocrine pancreatic insufficiency.

Valuation

MetricValue
Price$0.00
Market Cap$2618
P/E Ratio0.00
P/B Ratio0.00
P/S Ratio0.00
EPS (TTM)$-1.65
52-Week High$0.00
52-Week Low$0.00
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE340.00%
ROA-425.00%
ROCE3600.00%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio0.60

Annual Financials (USD)

Metric20132014201520162017
Revenue$0$0$3.0M$0$0
Operating Profit$-28.0M$-28.0M$-35.0M$-57.0M$-36.0M
Net Profit$-33.0M$-30.0M$-35.0M$-54.0M$-17.0M
EPS$-14.50$-11.13$-7.84$-10.38$-1.65
Op Margin——-1106.5%-39432.4%—

Balance Sheet (USD)

Metric20132014201520162017
Total Assets$37.0M$3.0M$48.0M$23.0M$4.0M
Total Liabilities$23.0M$6.0M$8.0M$11.0M$9.0M
Cash$26.0M$3.0M$47.0M$21.0M$2.0M
Borrowings$18.0M$0$0$0$0

Cash Flow (USD)

Metric20132014201520162017
Operating Cash Flow$-32.0M$-26.0M$-31.0M$-49.0M$-37.0M
Investing Cash Flow$-5.0M$10.0M$0$-2.0M$0
Financing Cash Flow$0$0$0$24.0M$0
Net Cash Flow$7.0M$-23.0M$44.0M$-26.0M$-19.0M
Free Cash Flow$-32.0M$-26.0M$-31.0M$-50.0M$-37.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA0.08
FCF Yield-1409472.88%
Quick Ratio0.68
Interest Coverage0.00
Return 1Y0.00%
Return 3Y0.00%
Return 5Y—

Ownership

Insiders Held0.00%
Institutions Held0.00%
Institutions Float Held0.00%
Institutional HolderSharesReport Date
Steigerwald, Gordon & Koch, Inc.252025-12-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CMRAComera Life Sciences Holdings, Inc. $0.00 — 0.00 $3074 0.00%
COTQFCotinga Pharmaceuticals Inc. $0.00 — 0.00 $2199 0.00%
GBIMGlobeImmune, Inc. $0.00 — 0.00 — 0.00%
NTIINeurobiological Technologies, Inc. $0.00 — 0.00 $2702 0.00%
OVITOncoVista Innovative Therapies, Inc. $0.00 — 0.00 $2356 0.00%

About Anthera Pharmaceuticals, Inc.

Anthera Pharmaceuticals, Inc., a biopharmaceutical enterprise, concentrates on developing and commercializing therapeutic solutions for conditions with significant unmet medical needs. The company's pipeline includes Sollpura, an investigational non-porcine pancreatic enzyme replacement therapy in Phase III clinical trials for individuals with exocrine pancreatic insufficiency. It is also advancing Blisibimod, currently in Phase II clinical evaluation for B-cell mediated autoimmune diseases, such as immunoglobulin A nephropathy (IgA nephropathy). Anthera holds licensing agreements with Amgen, Inc. and Eli Lilly and Company. Founded in 2004, the company's base of operations is in Houston, Texas.

Anthera Pharmaceuticals, Inc. (ANTH) stock trades at $0.00 with a market capitalization of $2618. The stock is valued at a price-to-earnings (P/E) ratio of 0.00, price-to-book of 0.00, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.00 and $0.00, and currently trades —% below its 52-week high.

On profitability, Anthera Pharmaceuticals, Inc. generates a return on equity (ROE) of 340.00% — well above the market average, a sign of a high-quality business, return on capital employed of 3600.00%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.anthera.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides